natgillin/translations-raw huggingface dataset:
The method of claim 4, the method further comprising: adding Layer 1 header to the time interleaved Layer 1 signaling data, wherein the Layer 1 header includes Layer 1 time interleaving information which indicates the time interleaving depth. 
Metoda iz patentnog zahtjeva 4, metoda nadalje obuhvaća: dodavanje zaglavlja razine 1 u signalni podatak razine 1 s umetnutim vremenom, pri čemu zaglavlje razine 1 uključuje informaciju umetanja vremena razine 1 koja ukazuje na dubinu umetanja vremena.
or salts thereof. The composition or use of any of the preceding claims, further comprising at least one compound selected from the group consisting of amiloride, amlexanox, bezafibrate, carbamazepine, gabapentin, ibudilast, leflunomide, losartan, methimazole, naproxen, nicardipine, nicergoline, perhexiline, pyrimethamine, sulodexide and telmisartan, or salts or prodrugs or derivatives of any purity or sustained release formulations thereof. The composition or use of any of the preceding claims, further comprising at least one compound selected from the group consisting of levodopa, pergolide, cabergoline, lisuride, pramipexole, ropinirole, apomorphine, selegiline, rasagiline, tolcapone, entacapone, clozapine, desipramine, citalopram, nortriptyline, paroxetine, atomoxetine, venlafaxine, amantadine, donepezil, rivastigmine and memantine, or salts or prodrugs or derivatives of any purity or sustained release formulations thereof. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se najmanje jedan preteča dopamina bira iz skupine koju čine levodopa i melevodopa, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem, najmanje jedan agonist dopaminskih receptora se bira iz skupine koju čine talipeksol, piribedil, rotigotin, bromokriptin, pergolid, kabergolin, lisurid, pramipeksol, ropinirol ili apomorfin, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem, a najmanje jedan inhibitor enzima koji metaboliziraju dopamin se bira iz skupine koju čine selegilin i rasagilin, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem.
of test item once a day for 4 days (from day 0 to day 3) 
ispitivanog primjerka jednom dnevno tijekom 4 dana (od dana 0 do dana 3)
Assembly according to claim 9 comprising two protrusions wherein each protrusion is situated on either side of the metallic casing, symmetrically in relation to the longitudinal axis of said casing. 
Kućište u skladu s patentnim zahtjevom 9, koje sadrži dvije izbočine (30), naznačeno time, da se svaka izbočina (30) nalazi na obje strane metalnog kućišta, simetrično u odnosu na uzdužnu os navedenog kućišta.
The genetically modified dermal micro-organ for use according to any one of claims 1-3, wherein said genetically modified dermal micro-organ further includes fat tissue. 
Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahtjeva 1 - 2, naznačen time, da navedeni dermalni mikroorgan sadrži masno tkivo.
50 20 A composition suitable for control of diseases caused by phytopathogens comprising a synergistically effective amount of 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I
in such a way that said actuator device is configured to be quickly prepared according to different configurations, in response to specific needs of an application of the valve actuator device. 
obliku utora (11), na takav način da se navedeni aktivator može brzo pripremiti u skladu s različitim konfiguracijama, kao odgovor na specifične zahtjeve primjene.
A compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, for use in the treatment of a colorectal cancer, a head and neck cancer, a pancreatic cancer, a breast cancer, a gastric cancer, a bladder cancer, a vulvar cancer, a leukemia, a lymphoma, a melanoma, a renal cell carcinoma, an ovarian cancer, a brain cancer, an osteosarcoma, or a lung cancer. 
4. Spoj u skladu s patentnim zahtjevom I, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća.
wherein the cancer sample has a staining uniformity for FOLR1 expression that is homogeneous; wherein 25-75% of cells of the cancer sample are stained for FOLR1 expression; or 
Cc) gdje se 25-75% stanica u uzorku raka oboji na eksprimiranje FOLR1; ili d) gdje se više od 75% stanica u uzorku raka oboji na eksprimiranje FOLR1.
A sunscreen product which has been available for several years, but which does not exhibit disadvantages such as the foregoing, is sold by Schering-Plough HealthCare Products, Inc., Memphis, Tenn. 
Proizvod za zaštitu od sunca koji je dostupan nekoliko godina, ali koji ne pokazuje nedostatke kao prethodno navedeni, prodaje Schering-Plough HealthCare Products, Inc., Memphis, Tenn.
Background of the Invention 
Pozadina ovog izuma
The method of claim 8, wherein in 5), the H2RuCl6 solution is stirred at 200 revolutions per minute for 1.5-2.5 hours. 
Postupak prema zahtjevu 8, naznačen time što se u koraku 5) otopina H,RuCLk miješa na 200 o/min tijekom 1.5-2.5 sata.
Alternative method for the preparation of compound 146 
Postupak za pripravu spoja s formulom: 34 O oN zo
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Reflux was maintained for 15minutes then temperature was allowed to cool to RT under stirring for 1h. 
Refluks se održava 15 minuta a potom se temperatura spusti na sobnu uz miješanje tijekom 1 sata.
The isolated cell of claim 7, wherein said cell is additionally negative for expression of a-smooth muscle actin, negative for expression of RANKL, positive for expression of NG2, positive for expression of osteoprotegerin, or exhibits inducible alkaline phosphatase activity. 
Izolirana stanica u skladu s patentnim zahtjevom 7, naznačena time što je navedena stanica uz to negativna na ekspresiju o-aktina iz glatkih mišića, negativna na ekspresiju RANKL, pozitivna na ekspresiju NG2, pozitivna na ekspresiju osteoprotegerina, ili pokazuje inducibilnu aktivnost alkalne fosfataze.
The composition according to claim 6 wherein the gamma-tocopherol is present in an amount of 100 mg to 3000 mg. 
Pripravak u skladu sa zahtjevom 6 naznačen time da je gama-tokoferol prisutan u količini od 100 mg do 3000 meg.
A vaccine for inhibiting proliferation of cells expressing genes of 1, 3, 5, 7, 9, 11, 13, 15 and/or 17 wherein the vaccine comprises a peptide of item 1-8 as the active ingredient. 
Cjepivo namijenjeno upotrebi u inhibiranju proliferacije stanice koja eksprimira gen iz SEQ ID NO: 1, naznačeno time što cjepivo sadrži peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 7 kao aktivni sastojak.
The cis-isomer was eluted first. 
Cis-izomer je eluiran prvi.
Racemic mixtures can be resolved into the optical pure enatiomers by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. 
Racemične smjese se mogu odijeliti u optički čiste enantiomere poznatim postupcima, na primjer, odijeljivanjem dijastereoizomernih soli s optički aktivnim kiselinama te oslobađanjem optički aktivnog amina spoja tretiranjem s bazom.
Such benign or malignant tumours may affect any tissue and include non-solid tumours such as leukaemia, multiple myeloma or lymphoma, and also solid tumours, for example bile duct, bone, bladder, brain/CNS, breast, colorectal, endometrial, gastric, head and neck, hepatic, lung, neuronal, oesophageal, ovarian, pancreatic, prostate, renal, skin, testicular, thyroid, uterine and vulval cancers. 
Takvi benigni ili maligni tumori mogu pogađati bilo koje tkivo i uključuju ne-krute tumore poput leukemije, multiplog mijeloma ili limfoma, i krute tumore, na primjer tumore žuči, kostiju, mjehura, mozga/CNS-a, grudi, kolorektalne, endometrijalne, gastričke, hepatičke, neuronske, ezofagealne, pankreatičke, renalne, testikularne i tiroidne tumore, kao i tumore glave i vrata, pluća, prostate, kože, uterusa i vulve.
The compound for use according to claim 12, wherein the ALK- or FAK-mediated condition or disorder is selected from: 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu ALK- ili FAK- posredovano stanje ili poremećaj je izabrano od androgeno nezavisnih karcinoma prostate, karcinoma dojki, i HNSCCs.
Another subset of compounds that is of interest relates to compounds of formula I wherein ring A is a phenyl or naphthyl group, a 5-6 membered monocyclic heteroaryl group or a 9-13 membered bicyclic or tricyclic heteroaryl group. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što je prsten A fenil ili naftil, monociklička heteroarilna skupina s 5-6 članova ili biciklička ili triciklička heteroarilna skupina s 9-13 članova.
The pharmaceutical composition according to claim 13, in the form of a gelatin capsule, a tablet, or a sachet. 
Farmaceutski sastav prema bilo kojem od zahtjeva 20-22 u obliku želatinaste kapsule, tablete ili vrećice.
Journal Paleolimnology 36: 245 - 257 A method to obtain a product comprising ferrous phosphate and ammonium, potassium or sodium phosphates, which is useful as a fertilizer and in the correction of iron chlorosis in plants, from waste materials or by-products containing phosphoric acid and/or phosphates and industrial products containing Fe(II), comprising the steps of: 
= osiguravanje otpadnih materijala ili sporednih proizvoda koji sadrže fosfornu kiselinu i/ili fosfate i, gdje je potrebno, podešavanje njihovog P sadržaja sa fosfornom kiselinom do 0.01 - 23 % P (m/m); b.
The pharmaceutical composition according to claim 2, comprising 80 mg of the hemisulfate salt of Compound (I). 
Hemisulfatna sol spoja (I) prema patentnom zahtjevu 1, gdje je navedena sol spoja (I) kristalna.
with a compound of formula XIV 
(XIII) reagira sa spojem formule XIV
The antibody or antigen binding fragment thereof of claim 1, further comprising a human IgG constant region. 
Antitijelo ili njegov antigen-vežući fragment iz zahtjeva 1, naznačen time, što sadrži još i konstantno područje humanog IgG.
reacting a compound of formula wherein X1 is halogen with a compound of formula to a compound of formula wherein the definitions are as described in claim 1 or 
reakcija spoja sljedeće formule 3: [image] gdje X1 je halogen, sa spojem sljedeće formule 4:
The method of any of the preceding claims, wherein the live, attenuated viruses are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus families and combinations thereof. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se žive, oslabljene viruse bira iz skupine koju čine porodice Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus i njihove kombinacije.
The process according to claim 1, wherein the decarboxylation reaction conditions are achieved by heating at a temperature of from 80 deg C to 250 deg C. 
Postupak prema zahtjevu 1, naznačen time, da se uvjeti za dekarboksilacijsku reakciju postižu zagrijavanjem na temperaturi od 80*C€ do 250%.
The aqueous pharmaceutical suspension according to claim 3, wherein the hydroxyethylcellulose is, by weight/volume (g/100 mL), 0.2% to 0.3%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidroksietilceluloza iznosi, težinski/volumno (g/100 ml), otprilike 0,2 % do otprilike 0,3 %.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 6, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25°C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37°C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1, 4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
The polypeptide of any one of paragraphs 1-3 wherein the polypeptide elicits a protective immune response in a mammalian host against strains of C.difficile. 
Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što polipeptid postiže zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
A medical device for treatment of a heart valve defect, in particular a heart valve failure or a heart valve stenosis in a patient, wherein the medical device has an insertion system (100) in accordance with one of the claims 1 to 13 and an expandable heart valve stent (150) accommodated in the catheter tip (10) of the insertion system (100). 
Medicinski proizvod za liječenje poremećaja srčanog zaliska, posebno zatajenja srčanog zaliska ili stenoze srčanog zaliska u bolesnika, pri čemu medicinski proizvod ima sustav za umetanje (100) prema jednom od zahtjeva 1 do 13 i šireći stent za srčani zalistak (150) smješten u vrhu katetera (10) sustava za umetanje (100).
The Smith-Waterman homology search algorithm is taught in reference 64. 
Smith-Waterman algoritam za traženje homologije se tumači u referenci 64.
The composition for use according to claim 1, wherein the peroxide is selected from the group consisting of hydrogen peroxide at 3.5% to 6% of the total composition, carbamide peroxide at 10% to 16% of the total composition, and benzoyl peroxide at 2.5% to 5% of the total composition The composition for use according to claim 1 or 2, which further comprises at least one hydrophilic gelling agent selected from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol(RTM) polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1, gdje peroksid je odabran iz grupe koja se sastoji od vodik peroksida pri 3.5% do 6% ukupne kompozicije, karbamid peroksida pri 10% do 16% ukupne kompozicije, i benzoil peroksida pri 2.5% do 5% ukupne kompozicije Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
A method according to claim 2 wherein the metal is an alkali or alkali earth metal. 
Postupak sukladno patentnom zahtjevu 2, naznačen time što je metal alkalni ili zemno alkalijski metal.
Table 5- Effects of Isomer B in a transgenic mice model of Huntington's disease Phase I: Efficacy in acute study, administration from Day 0 to Day 3 - Simplified Irwin test 
Tabela 5- Učinci Izomera B u transgenskom mišjem modelu Huntington-ove bolesti Faza I: Učinkovitost u akutnom proučavanju, primjena od Dana 0 do Dana 3 -Pojednostavljen Irwin test tg 429i kB+dkebi Ek Beno | gen rect da
A composition for use according to claim 6 wherein said excipient comprises a medium chain triglyceride, said triglyceride comprising a minimum of 95 per cent of saturated fatty acids with 8 and 10 carbon atoms. 
Kompozicija prema patentnom zahtjevu 6, naznačena time što navedeni triglicerid sadrži minimalno 95 postotaka zasićenih masnih kiselina sa 8 i 10 atoma ugljika.
The process as claimed in claim 1, wherein the temperature used in Step (vi) is 25 °C to 30 °C. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je temperatura korištena u Koraku (vi) 25 "C do 30 "€.
The compounds mentioned herein are useful in the treatment and/or prophylaxis of any one of or any combination of the following: pre-diabetic insulin resistance syndrome, the resulting complications thereof, insulin resistance, Type II or non-insulin dependent diabetes, dyslipidemia, hyperglycemia, obesity and the complications associated with diabetes including cardiovascular disease, especially arteriosclerosis. 
Spojevi spomenuti u ovoj specifikaciji korisni su u liječenju i(li) profilaksi bilo kojeg od ili bilo koje kombinacije sljedećeg: sindroma preddijabetične otpornosti na inzulin, rezultirajućih komplikacija, otpornosti na inzulin, dijabetesa tip II, tj. dijabetesa neovisnog o inzulinu, dislipidemije, hiperglikemije, pretilosti i komplikacija povezanih s dijabetesom, uključujući kardiovaskularne bolesti, osobito arteriosklerozu.
In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. 
Kod pripravaka pogodnih za perkutanu aplikaciju, nosač eventualno sadržava tvar koja povećava penetraciju i/ili odgovarajuće sredstvo za vlaženje, eventualno u kombinaciji s odgovarajućim aditivima bilo koje prirode u malim omjerima, pri čemu aditivi ne uzrokuju signifikantni štetni učinak na koži.
Therefore the origin of CO2 can be either in situ or supplied externally or even a combination thereof. Irrespective of the optional addition of gaseous CO2 to the slurry, the process of the present invention further comprises the step e) which is contacting said aqueous calcium carbonate containing mineral slurry of step a) with said acid of step b) and with said in situ generated and/or externally supplied CO2 of step d), said contacting being made under stirring or mixing conditions. 
Postupak prema jednom od zahtjeva 1 do 9, naznačen time da se dodavanje barem jedne kiseline koja se otapa u vodi iz koraka b) i dovođenje u kontakt navedene vodene suspenzije koja sadrži kalcijev karbonat koji sadrži mineral iz koraka a) s navedenom kiselinom iz koraka b) i s navedenim CO, nastalim na licu mjesta i/ili koji se dobavlja iz vanjskog izvora iz koraka c) odvija u miješanom reaktoru uz miješanje tako da nastaje u biti laminarno strujanje.
The method of item 12, wherein the target cell is a human tumor cell, and the therapeutic specifically binds an epitope of the human tumor cell. 
(d) humana tumorska stanica, a terapijsko antitijelo se specifično vezuje za epitop humane tumorske stanice.
One aspect of the present invention pertains to PEG, as described herein, for use in a method of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis by topical administration. 
PATENTNI ZAHTJEVI Polietilen glikol, naznačen time, da se upotrebljava u postupku smanjivanja brzine recidiva, odgađanja recidiva i/ili sprečavanja recidiva herpesa labialis pomoću topikalne primjene; pri čemu je razdoblje primjene najmanje 4 tjedna.
A pharmaceutical composition comprising an oligonucleotide as defined in any one of claims 1 to 4 and/or the vector of claim 5, a pharmaceutical acceptable carrier, and optionally combined with an antisense oligonucleotide which is able to induce or promote skipping of at least one of exon 51, 53, 55, 57, 59 or 69 of the dystrophin premRNA of a patient. 
Farmaceutski sastav obuhvaća besmisleni oligonukleotid kako je definiran u bilo kojem od patentnih zahtjeva 1-14 i/ili vektor iz patentnog zahtjeva 15, farmaceutski prihvatljivi nosač.
The aqueous pharmaceutical suspension according to claim 3, further comprising, by weight/volume (g/100 mL), 1.5% to 2.0% of microcrystalline cellulose. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 1,5 % do otprilike 2,0 % mikrokristalne celuloze.
Adjusting the gain parameter can include enabling gain attenuation to reduce a gain value corresponding to a frame of the audio signal. 
Postupak prema zahtjevu 1, gdje podešavanje parametra pojačanja podrazumijeva omogućavanje slabljenja pojačanja kako bi se umanjila vrijednost pojačanja koja odgovara sklopu audio signala.
Consequently, in another aspect, the present invention relates to the use of the antibody of the invention or the binding molecule of the invention for sensitizing tumor cells in a patient for the treatment with a chemotherapeutic drug or with radiotherapy. 
Vežuća molekula koja se može vezati na LI u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je namijenjena upotrebi u postupku sensibiliziranja tumorskih stanica kod pacijenta radi liječenja kemoterapijskom lijekom ili radioterapijom.
Mineral filler product according to claim 1 or 2, characterized in that in the case of the subsequent application of the mineral filler in breathable or extrusion coating films, this mineral filler is a calcium carbonate and/or dolomite, and is more preferably a marble and/or dolomite. 
Postupak prema zahtjevima 1 ili 2, naznačen time da mineralno punilo odnosno punila pružena u koraku (a) postupka su mineralna punila koja sadrže kalcijev karbonat i/ili pločaste minerale.
For example, N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylamino-methyl]benzamide polymorph B can be used as medicament for the treatment of malignant tumors, auto-immune diseases, dermatological diseases and parasitism. 
Uporaba N-(2-aminofenil)-4-[N-(piridin-3-il)metoksikarbonilaminometiljbenzamid polimorfa B, naznačena time da se odnosi na proizvodnju lijeka za liječenje malignih tumora, autoimunih bolesti, kožnih bolesti i parazitizama.
A composition comprising a muscarinic receptor agonist and an inhibitor of thyroid hormone synthesis for the treatment of CMT in a subject, wherein the treatment further comprises a step of determining whether the patient has CMT1A. 
Sastav za uporabu u skladu s patentnim zahtjevom 5, pri čemu liječenje nadalje obuhvaća korak određivanja ima li pacijent CMTIA.
The disclosure there also preferably relates to an atomiser with a shape similar to that of a cylinder and a size of length about 9 cm to about 15 cm long and of width about 2 cm to about 5 cm, and with a nozzle jet spread of 20° to 160°, preferably of 80° to 100°. 
Ovaj opis odnosi se ponajprije na atomizer oblika sličnog cilindru i duljine pribl. 9 cm do pribl. 15 cm, te širine pribl. 2 cm do pribl. 5 cm, i s mlazom raspršenim iz mlaznice od 20" do 160", ponajprije od 80" do 100%.
a framework (120) connected to the semisubmersible platform, 
okvira (120) pričvršćenog na poluuronjivu platformu, -
The immunogenic composition for use according to any one of claims 1-3 wherein the Streptococcus pneumoniae infection occurs in blood and the free concentration of Zn2+ in the blood is less than 10nM, 1nM, 100pM or 10pM as measured from blood serum. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u krvi, a slobodna koncentracija Zn** u krvi je manja od 10nM, 1 nM, 100 pM ili 10 pM, što je izmjereno u krvnom serumu.